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This study examined cancer research stories on the BBC web archive (July 1998–June 2006). There were about 260 BBC stories per
year, of which about 170 were classed as relevant to reports of cancer research. The stories focused heavily on breast cancer, and
over one-third of them mentioned this (compared with a cancer disease burden of 13%); the next most covered sites were lung and
prostate cancers, although the former was much less mentioned than its cancer disease burden of almost 20% would have suggested.
The focus of the stories was often on new or improved drugs or vaccines (20% of stories), with lifestyle choices (12%), genetic
developments (9%), and food and drink (8%) also featuring fairly prominently. The BBC stories cited about 1380 research papers that
could be identified as journal articles. About three-quarters of the cited papers were in the field of cancer. The papers of these
authors came from over 60 countries, and 40% were from the United Kingdom and 36% from the United States. UK cancer research
was heavily overcited, by about 6:1, relative to its presence in world oncology research and US research was cited about in
proportion. That of most other countries, especially Japan, Germany, and Austria, was relatively undercited. These cited papers also
acknowledged more funding bodies. Most of the BBC stories were put in context by external commentators, of whom the large
majority was from the UK’s cancer research charities.
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UK cancer research has enjoyed substantial sociopolitical focus
over the last 8 years with the merger of the two largest charities
and the creation of the National Cancer Research Institute. Such
focus has inevitably given rise to a greater need to demonstrate the
impact of national research expenditure and to influence health-
care policy (Glass, 2002). Mass media are the nexus between public
and policy agenda and are highly influential in shaping discourses
about health and research. The way in which news media affect
the public is complex and diverse. Recognised effects include
informing audiences (Rees and Bath, 2000), agenda-setting,
framing (Passalacqua et al, 2004) and persuading (Iyengar,
1997). There is now a substantial corpus of literature demonstrat-
ing the impact of media on shaping public opinion towards
countries’ health-care systems (Benelli, 2003; Collins et al, 2006),
and how newspapers targeted at particular ethnic groups can vary
in their approach (Hoffman-Goetz and Friedman, 2005). In
addition, there have been studies of how health-related issues
have been portrayed in the media around particular diseases
(Brown et al, 2001), the uptake of health care (Mintzes et al, 2003)
and screening for cancer (Jones, 2004; Schroy et al, 2008), and
pharmaceutical coverage (Cassels et al, 2003), particularly in
certain media-conscious countries such as Australia, Canada, the
United Kingdom and the United States. However, the mass media
have also given misleading information about the supposedly
beneficial effects of complementary and alternative therapies
(Milazzo and Ernst, 2006; Weeks et al, 2007).
The nature and impact of science in the media have also become
a major policy concern (Conduit, 2001). Commentators on this
subject have given vent to a range of complaints, such as the
accuracy of media reporting (MacDonald and Hoffman-Goetz,
2002; MacKenzie et al, 2007), the pressure of commercialisation
and the challenge of media hype (Ooi and Chapman, 2003;
Caulfield, 2004). However, the impact of disease-specific research
on the media remains a relatively underdeveloped and under-
studied area. This study set out to describe in a quantitative
manner the impact of cancer research on a major conduit of
research stories – the BBC news website (http://www.bbc.co.uk) –
which is accessed by some 52% of the UK online universe, some
13.2 million people annually. This source is also used for both the
national and international press, TV, and radio stories, and thus
provides an ideal surrogate for the determination of overall media
impact. The goals of this study were broadly to map the impact of
research funding organisations and their commentators on
reported cancer research stories, to determine the extent to which
the media reporting of cancer research is ‘balanced’ in terms of its
site-specific coverage and domains of research, and finally the
degree to which media reports of cancer research by the BBC
reflect the international impact and indeed whether such reporting
in turn influences the citation of papers.
METHODOLOGY
The search of the BBC archive was limited to the health section and
to the 8-year period from July 1998 to June 2006. The headline,
date and abstract of the stories were copied from the BBC website
to a spreadsheet, and they were each read through (by GL and ST).
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sThey were first coded for relevance (3 for being relevant because
they cited research; 2 for being partly relevant, usually because
they reported future research or some survey of patient attitudes
or experiences; 1 for not relevant – often a report of an individual
case). For example, stories with headlines such as ‘Vitamin D can
lower cancer risk’ or ‘Virus clue to cervical cancer jab’ were coded
3, and those headed by ‘Boys less likely to eat healthily’ or ‘Ethnic
minorities less breast aware’ were coded 2.
Selected data (cancer site – e.g., breast or lung, scientists
involved, their institution(s), the journal in which any cited paper
was published, and details of any commentators) were then
extracted and recorded on the spreadsheet for each story. The
percentages of BBC stories focusing on different cancer sites were
compared with the UK’s burden of disease from these particular
cancers, measured in Disability Adjusted Life Years (DALYs)
(Murray and Lopez, 1996), as given by the World Health
Organization for 2002, and relative to the burden from all cancer
– this gives a fairer impression of the effect of different cancer
types on society than the numbers of deaths. The stories were also
coded for the basis of the work being reported, namely drug-
related, environmental, food and drink, genetics, job, lifestyle, as 1
or 0 in each of six columns on the spreadsheet.
If a story cited one (or more) research paper, then the
bibliographic details of these were sought. They could usually be
identified readily because the name of the journal was given, but
occasionally this turned out to be given incorrectly. Some
conference presentations could be identified with meeting
abstracts in relevant journals, although for others there did not
appear to be a corresponding publication. The addresses of all the
authors were also carefully recorded, with at least three elements
present: the institution name, the city name (and region/state and
postcode, if present), and the country. These addresses could then
be analysed by means of special macros to reveal both integer and
fractional counts of countries. For example, a paper with one UK
and two US addresses would be counted as unity for both countries
on an integer count basis, but 0.33 and 0.67, respectively, on a
fractional count basis.
The research level (RL) of the cited papers was determined to
see if the BBC stories primarily covered clinical work, as might
have been expected, or sampled fairly the whole range of cancer
research as reported in the peer-reviewed serial literature. The
research level was calculated on the basis of the journal in which
the papers were published as a decimal number between 1 and 4,
where 1¼clinical observation and 4¼basic research. This was
determined from the titles of the papers appearing in the given
journal that had a biomedical word in their addresses (Lewison
and Paraje, 2004). Over 100 ‘clinical’ title words and a similar
number of ‘basic’ words were used to determine if a journal paper
was clinical, basic, or both: clinical papers were given an RL of
unity, basic papers an RL of 4, and ‘both’ papers an RL of 2.5. From
these values, it was possible to calculate the mean RL for papers in
the journal. Some examples of leading journals with their RLs are
given in Table 1.
The potential citation impact (PCI) of the cited papers was also
based on their journal and was determined as the mean number of
citations received by papers in the journal in the year of
publication and four subsequent years. However, as this gives
values that do not correspond well to the subjective views of both
researchers and administrators (Lewison, 1995, 1998) on the
relative importance of papers in different journals (which are in
the range 1–5 or 6), a logarithmic function (LOG) was also
calculated: 1þ2log10(1þPCI), whose values range from 1 for
‘ordinary’ journals up to 5 for ‘top’ journals such as Nature. Some
examples are shown in Table 1.
The actual citation impact (ACI) of those cited papers published
in 1998–2001 with addresses only in the United Kingdom, or in
the United States (in practice, just over 300 papers) was
determined by the counting of citations to them in their year of
publication and 4 subsequent years. The address details of all the
citing papers were also determined. This was done to gauge
whether citation by the BBC influenced the papers’ impact on
other scientists.
The individual cited papers were also looked up to record their
funding acknowledgements. Each such acknowledgement was
recorded with four codes: a trigraph to identify the individual
organisation (e.g., MRC¼Medical Research Council), a letter to
denote the type of funding (I¼intramural, E¼extramural,
P¼personal, and K¼in kind), a digraph to denote the organisa-
tion’s category (e.g., CH¼collecting charity, FO¼endowed
foundation, GA¼government agency, and IP¼pharma industry),
and another digraph to denote the country of the organisation,
taken from the International Standards Organization list. A few
funding bodies were European, and coded EU; and some were
international and coded XN.
All of these parameters – geography, RL, PCI, ACI, and funding
– were also compared with the corresponding values (both means
and distributions) for world oncology research papers for relevant
years so as to normalise the results and show whether the papers
cited by the BBC were, or were not, unbiased samples from the
larger population. The world oncology research files were derived
from the Science Citation Index by means of a ‘filter’ (Cambrosio
et al, 2006) that was based on specialist cancer journals and title
keywords; they contained details of about 35000 papers per year.
Many of the BBC stories attempted to put the research news in
context with comments from external experts. The names of these
people, and their organisations – usually cancer research funders –
were recorded. Some unification of the organisation names was
needed, and their percentage presence among the commentators
was compared with their presence among the funders of UK cancer
research in 2000–2001 (Webster et al, 2003) so as to normalise the
Table 1 List of some leading journals cited in BBC cancer stories, with the number (N) and percentage of papers cited, their research level in 2000–2004
(RL1¼clinical; RL4¼basic), PCI over 5 years and log value (LOG)
Journal N % RL PCI LOG
Nature 55 3.9 3.48 100.6 5.0
New England Journal of Medicine 53 3.8 1.16 95.3 5.0
Journal of the National Cancer Institute 71 5.1 1.79 52.1 4.4
JAMA – Journal of the American Medical Association 53 3.8 1.07 49.9 4.4
Proceedings of the National Academy of Sciences of the United States of America 50 3.6 3.70 43.2 4.3
Cancer Research 43 3.1 3.29 34.6 4.1
Lancet 155 11.1 1.24 29.7 4.0
British Medical Journal 102 7.3 1.04 14.4 3.4
British Journal of Cancer 107 7.7 2.04 14.0 3.3
European Journal of Cancer 24 1.7 1.63 9.7 3.1
Journal of Epidemiology and Community Health 11 0.8 1.07 7.9 2.9
LOG¼logarithmic function; PCI¼potential citation impact; RL¼research level. Specialist cancer journals shown in bold.
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cancer research funding community in the United Kingdom.
RESULTS
Numbers of stories and cancer sites
Figure 1 shows the numbers of BBC cancer research stories in each
of the 9 years of the study. Relevant stories categorised as ‘3’ are
shown in black. The number of stories reached a peak in 2002 and
has since declined.
Of the relevant stories, some mentioned several cancer sites, and
others did not mention any particular site. What was clear was that
breast cancer dominated, with over one-third of all stories (where
one or more sites were mentioned) referring to it. Lung cancer
(10%) came a rather poor second, followed by prostate (8%) and
skin cancer (6%). Figure 2 shows a plot of percentage of mentions
of different cancer sites against percentage of total cancer DALYs
for the UK for these sites. This plot makes it clear that cancers of
breast, cervix, and skin are overreported in relation to the burden
they cause. Of the major cancer types, the biggest ‘deficiency’ is in
lung cancer, where there are far fewer stories than the burden of
this disease would suggest. It causes 20% of all cancer DALYs, but
is only mentioned in 10% of the BBC stories.
Story features
New and improved drugs (and a few about vaccines) are the
dominant type of story, followed by ones on lifestyle (particularly
smoking and sunbathing), genetics, and food and drink (including
dietary supplements such as vitamins) (Figure 3). Coverage of new
drugs peaked in 2001, and then declined; the recent rise is largely
due to stories about whether herceptin should be prescribed on the
NHS for the early-stage breast cancer. Genetics stories rose to a peak
in 2002 and have also declined somewhat. Meanwhile, stories about
food and drink have steadily increased in presence; this may also
reflect a generally increasing interest in food, including school
dinners. But stories about occupational risks, never numerous,
appear to have declined steadily; this probably reflects the continuing
decline of ‘dirty’ industries in western Europe and North America
and their replacement with relatively safer service jobs.
Cancer research papers cited by the BBC stories: journals
and geography
About two-thirds of the BBC stories reported cancer research
advances, and some stories cited more than one research paper. In
total, there were 1394 cited research papers in 253 different
journals that could be identified from the information given in the
story (37 papers could not be identified). Some of the leading
journals are listed in Table 1, and the cancer journals are shown in
bold: altogether, they account for 42 of the total, and for 443
papers, or 32%. (This is fairly typical: in most biomedical sub-
fields, only about one-third of the papers are in specialist journals;
Lewison, 1996.)
Of the cited papers, 1036 (76% of the identified papers) fell
within the oncology subfield (ONCOL), as defined by the Cancer
Research UK oncology filter, described above. The cited papers
included authors from 62 different countries, but the United
Kingdom and the United States each had a large proportion of the
total on both a fractional and an integer count bases (Figure 4).
Figure 4 shows the percentage presence of 18 leading countries
in the papers cited by the BBC stories plotted against their
presence in oncology research. Although it looks as if the stories
were dominated by research from just two countries, the US papers
were cited closely in proportion to their presence in oncology
research in the 5 years, 2000–2004, and it is just the UK papers
that were, not altogether surprisingly, overcited. Indeed a very
similar result was found for biomedical research papers cited in
UK newspaper stories in 2001 (Lewison, 2002). The papers of two
European countries (Denmark and Ireland) were also overcited,
but not to the same extent. Research carried out in most European
countries was undercited, especially Germany and Austria, as was
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Figure 1 Annual numbers of BBC stories on ‘cancerþresearch’ or
‘cancerþstudy’ from July 1998 to June 2006. Stories of high relevance
(rel¼3) are shown in black.
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Figure 2 Correlation between the relative burden of different cancers
(DALYs, 2002, WHO estimate) and the numbers of BBC stories
mentioning the different cancer sites, 1998–2006.
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Figure 3 Variation of relative presence of four types of story among
BBC cancer research stories of 3-year moving averages. (Environmental and
lifestyle stories were relatively constant at 5 and 12%, respectively.)
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sthat of Japan. If UK contributions both to papers cited by the BBC and
to oncology are removed, a few more countries (Canada, Netherlands,
and Switzerland) now appear to be slightly ‘above the line’.
The difference between the observed presence (number of
papers and fractional counts) and that expected from the oncology
file can be determined as statistically significant or not. For
Ireland, the difference is not significant (PB10%), but for
Denmark it is PB0.2%, and for the larger continental countries,
the (negative) difference is highly significant (Po0.01%).
Cancer research papers cited by the BBC stories: RL and
PCI
In this section, a comparison is made between the distribution of
the RLs of the papers cited in BBC stories and those of oncology
research papers from 2000–2004. Similarly, the distributions of a log
function (LOG) of PCI (based on the journals in which the papers
were published) have also been compared. For RL, the comparison
takes the form of cumulative distribution curves (see Figure 5); for
LOG, distributions are shown as a chart in Figure 6, although mean
values have also been calculated and are shown in Table 2.
Papers cited by the BBC stories are, on average, more clinical
than the oncology papers (Figure 5) and they are also in much
more highly cited journals (Figure 6). The mean values of PCI, and
of its corresponding log function (LOG), have been rising slowly
with time, but they are far below the mean value for the papers
cited by the BBC stories. By way of comparison, a mean RL of 2.28
corresponds to Journal of Cancer Research and Clinical Oncology;a
mean RL of 2.06 corresponds to Neoplasma. A mean PCI of 13.9
corresponds to British Journal of Cancer or to Journal of Mammary
Gland Biology and Neoplasia, and a mean PCI of 34 corresponds to
Seminars in Cancer Biology.
ACI of papers cited in BBC stories
The mass media are not only seen, heard, and read by the public,
but they also attract the attention of the research community. For
example, it was found that The New York Times had a marked
effect on the frequency with which the research articles that it
wrote about were cited from a comparison of the numbers of
citations to articles in the New England Journal of Medicine
published before, during, and after a 3-month strike at that
newspaper (Phillips et al, 1991). We hypothesised that coverage by
the BBC might have a similar effect. However, in the absence of the
unique occurrence of the strike (when a paper of record was
prepared but not distributed), it is more difficult to normalise and
determine the counter-factual situation.
We applied two tests to see whether citations by the BBC made a
difference to the impact of the papers on the research community.
First, we compared the mean actual citation counts with samples of
oncology papers with only UK authors, or only US authors, from
the year 2000 with their mean potential citation counts, that is, the
expected citation scores if they were typical of papers published in
the same journals. We then compared the same indicators for two
sets of BBC-cited papers, again with just UK authors or just US
ones. (The reason for the geographical exclusiveness is that it is
known that multinational papers tend to be published in higher
impact journals and to receive more citations, but the effect is
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Figure 4 Comparison between percentage presence (fractional counts)
of 18 countries in papers cited by BBC stories and their presence in
oncology research (2000–2004). Solid diagonal shows equal relationship;
dashed diagonal shows relationship expected when UK contributions to
papers are removed from the international pool.
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papers cited by the BBC (black bars) and world oncology papers, 2000–
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Table 2 Mean values of RL, of PCI and of a log function of PCI
[1+2log10(1+PCI)] (LOG) for oncology papers from years 2000–2004
(ONCOL), and for the papers cited by the BBC cancer stories (BBC)
ONCOL 2000 2001 2002 2003 2004 BBC
Mean RL 2.26 2.28 2.27 2.28 2.29 2.06
Mean PCI 13.4 13.7 13.9 13.9 14.3 34.0
Mean LOG 3.07 3.09 3.11 3.11 3.14 3.79
LOG¼logarithmic function; PCI¼potential citation impact; RL¼research level.
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ssomewhat dependent on the numbers of countries involved and
their identity, and also on the numbers of funding sources
acknowledged; Narin et al, 1991; Lewison, 2003.) The results are
shown in Table 3.
Both sets of oncology papers received fewer citations, on
average, than might have been expected from the journals in which
they were published, but both sets of papers cited by the BBC
received more citations than expected. This suggests either that the
BBC reporters were prescient in selecting the papers that would be
highly cited or that they influenced the process – perhaps the latter
explanation is more likely, as BBC coverage may well have led to
stories in the newspapers as well and thus to greater publicity for
the papers, and not only in the UK. They may also have been pre-
selected by the journal staff, who often send out press notices to
draw attention to papers thought to be of particular interest and
significance.
The second test was to see whether citations in BBC stories had a
disproportionate influence on UK scientists, as measured by the
propensity of these papers to have a higher percentage of their
subsequent citations from the United Kingdom. For this purpose,
we downloaded bibliographic details of all the citing papers from
the above table (namely, 5466þ11007þ3599þ8950¼29022)
and analysed them geographically so as to reveal the (fractional
count) contributions of the different citing countries. The results
are shown in Table 4.
Data for Canadian citing authors have been provided to show
that for a third country, the percentages of their citations are
almost constant. The column head ‘UK, %’ shows that UK authors
were more frequent citers of both groups of papers mentioned in
the BBC stories, by 28.2/24.1 or by þ17% for the UK papers and
by 5.9/5.0 or by þ18% for the US ones. The effect is not large, but
the differences between the observed and expected values on the
null hypothesis are statistically significant (P¼0.003% for the US
papers, and even less for the UK ones). The authors from US were
less likely to cite the UK articles in BBC stories, but they were more
likely to cite the US papers, which probably also received coverage
in their own country’s media.
The funding of the cited research papers
Altogether, funding acknowledgements were recorded for 1385
papers, of which 594 had an address in the United Kingdom and
647 had an address in the United States. Of these 1385 papers, 290
or 21% had no recorded funding, and the research was probably
supported by general university funds or those of the relevant
hospital or state health service based on the presence of university
or hospital addresses. The others had one or more funding
acknowledgements, the maximum number being 39 for two
papers. Figure 7 shows the distribution of the numbers of funders,
with, for comparison, the corresponding percentages found for a
large structured sample of oncology papers from 2003.
It is clear that the papers cited by the BBC stories have more
funding acknowledgements and that, in particular, relatively few
have ‘no’ funding – 21% compared with 34% for the sample of
oncology papers. An analysis was then made of the sector of the
funding bodies for UK and US papers. For this purpose, funders
were divided into four main sectors, namely national government
(including, local and regional authorities), national private non-
profit, industrial, and international. There were also other funders,
public and PNP sector organizations from third countries. The
sectoral analysis is shown in Table 5.
As would be expected from Figure 7, there are many fewer
‘unfunded’ papers than expected for both the United Kingdom and
the United States. In the United Kingdom, funding is dominated by
the private non-profit sector, but in the United States it is led by
the government sector, with much support coming from the
National Cancer Institute (NCI) and from the National Institutes of
Health (NIH) more generally. Industry funds about one-sixth of
the papers cited by the BBC in both countries. The international
funding is primarily from the European Commission, which was
acknowledged on 48 of the papers cited by the BBC, of which 35
were from the United Kingdom and 9 from the United States (all,
of course, co-authored with a European Union Member State). By
contrast, the World Health Organization (WHO) was acknowl-
edged on only twelve papers cited by the BBC, of which four were
from the United Kingdom and six from the United States, and two
from both countries.
Commentators on the research findings
A notable feature of most of the BBC stories was that external
experts were asked to comment on the significance of the results,
and what they might mean for the treatment of cancer patients.
Altogether, there were as many as 724 different commentators over
the 8-year period, and they made a total of 1842 comments on 1272
stories, with an average of 1.45 quotes on each story where a
commentator was quoted. Of the 12 most frequent commentators
(one of whom was RS) with 19 or more appearances, no fewer than
10 were from Cancer Research UK, and the other 2 were also from
cancer research charities (Breakthrough Breast Cancer and the
Table 3 Comparisons of mean actual and potential citation impact over
five years of four groups of papers: UK- and US-authored, and in oncology
research (ONCOL, 2000) and cited by the BBC (1998–2001)
Group Papers Cites Mean ACI Mean PCI Ratio
UK ONCOL 441 5466 12.4 14.8 0.83
US ONCOL 674 11007 16.3 18.1 0.90
UK BBC 154 3599 23.4 20.2 1.16
US BBC 152 8950 58.9 46.7 1.26
ACI¼actual citation impact; PCI¼potential citation impact.
Table 4 Geographical analysis (Canada, the United Kingdom, and the
United States; fractional counts) of papers citing to four groups of papers
(see Table)
Group Cites CA cites CA, % UK cites UK, % US cites US, %
UK ONCOL 5466 150 2.7 1317 24.1 1670 30.6
US ONCOL 11007 325 2.9 553 5.0 5815 52.8
UK BBC 3599 98 2.7 1014 28.2 1033 28.7
US BBC 8950 252 2.8 530 5.9 4990 55.8
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Figure 7 Distribution of numbers of funding bodies acknowledged on
papers cited by BBC cancer stories, 1998–2006, and on a sample of 2115
oncology papers from 2003.
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sProstate Cancer Charity). Public sector commentators were
relatively rare. They included Julietta Patnick of the NHS Cancer
Screening Programme, Mike Richards, the National Cancer
Director, and also 10 Members of Parliament. The Medical
Research Council (MRC) commented only on 15 stories, just over
1%. Figure 8 shows that there is no correlation at all between
support for cancer research in the United Kingdom and invitations
to comment, except for Cancer Research UK and the Department
of Health (UK), for which the invitations are in fair proportion.
Representatives of the Wellcome Trust, which, despite formally
eschewing the funding of clinical cancer research in the United
Kingdom (Wellcome Trust, 2008), funded about 7% of UK cancer
research in 2000–2001, did not comment at all, and two cancer
charities based outside London, the Yorkshire Research Campaign
in Harrogate and the Association for International Cancer
Research in Fife, Scotland (both funding 2.3% of UK cancer in
those years) only commented once and twice, respectively.
These findings suggest that the BBC (in common with other
news media) see it as highly desirable to put new research findings
in context. Most commentators were enthusiastic and viewed the
research as very useful, but they counselled strongly against
premature optimism and stressed that more research work was
needed, and more time, before patients were likely to benefit. The
frequency with which the BBC reporters (nearly all anonymous,
unlike in the newspapers) turned to the cancer charities in London
for interpretation of the research news suggests that this path has
become well-worn and, in turn, that the charities have become
adept at presenting themselves to the public even if only in the
reflected glory of research done by others. Although the MRC and
the Wellcome Trust are active in cancer research, one would not
realise this from the BBC stories.
DISCUSSION
The BBC archive, which closely approximates to the items
broadcast on radio and television, is a fecund source of
bibliometric data (Ghosh, 2007). It provides a new perspective
on biomedical research and helps reveal its likely impact on the
wider public. In this study, we have found consistently high levels
of BBC cancer research stories. The impetus of charitable mergers
and additional government support to cancer research appears to
have been reflected in the absolute numbers of cancer research
stories reaching a peak in 2002. However, the wave of activity
appears to have hit a high tide mark and has been settling back
down over the last 3 years to pre-2000 levels.
We have found, relative to the DALY impact, a strong focus on
breast cancer in these stories. Within the cancer field, breast
cancer is acknowledged to have strong personal identity and
worldwide advocacy stemming from activism in the late 1980s
and a research track record of delivering new and effective
management in the form of greater understanding of pathogenesis
and risk factors (e.g., Million Women Study/Hormone Replace-
ment Therapy) through surgical techniques (Sentinel Node Biopsy)
and drugs (e.g., the wide range of endocrine therapies). This self-
reinforcing cycle has filtered through to generate huge media
exposure, when compared with other site-specific cancers. This
has been a mixed blessing. Although this clearly provides greater
breast awareness and potentially increases charitable giving to
breast cancer (although there is no direct evidence that this
happens), we know that women greatly overestimate their lifetime
risk of breast cancer (Pohls et al, 2004). Why? The plausible
hypothesis is that the greater exposure of women to breast cancer
stories, particularly those associated with risk factors, leads to a
resetting of the cultural milieu in which women estimate their risk.
A number of site-specific cancers fare poorly in their media
exposure – lung, upper GI tract, and so on. For the majority of
these cancers (lymphoma being an exception to this observation),
progress in controlling and curing them has been glacial. Mortality
is high and survival poor. Thus, a lack of year-on-year treatment
progress coupled to poor outcomes has inevitably led to poor
media exposure. As art reflects society, so the media are reflecting
progress – those cancers for which we are ahead of the curve (e.g.,
breast), those on the curve (e.g., colorectal), and those that are
behind (e.g., upper GI tract and lung). Media trends in coverage of
site-specific cancers over time appear from our data to be an
additional tool to inform policymakers not only of active/
successful research domains but also of those that have developed
strong interest groups (Howlett and Ramesh, 2003).
In a typical year, there will be about 240 BBC stories on cancer
research, of which about 160 will cite research papers. The main
focus is on new and improved drugs that could be used to treat
cancer. Drugs dominate research reports and the trend is
increasing. Such stories overwhelmingly emphasise breakthroughs,
and, as previously reported, do a poor job in reflecting the relative
contribution of the drug in question and indeed the multitude of
giants on whose shoulders such new technologies have come into
being (SIRC, 2001). Again the media are reflecting the dominant
research paradigm in cancer – that of drug discovery and
development – and providing a surrogate marker not only for
the activity levels of research in this area (which are very high
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Figure 8 A plot of percentage presence of UK cancer funding
organisations as commentators on BBC stories of cancer research,
1998–2006, against their contribution to UK cancer research funding,
2000–2001.
Table 5 Sectoral analysis of numbers (N) and percent of different
funding bodies acknowledged on UK and US papers cited in BBC
cancer research stories with, for comparison, UK oncology papers from
2000–2001 (ONC, n¼5385) and US oncology papers from 2003 (ONC,
n¼472)
UK, N UK, % ONC % US, N US, % ONC %
All papers 594 100 100 647 100.0 100
Government 170 28.6 18.3 396 61.2 57.6
Private non-profit 344 57.9 43.3 288 44.5 36.7
Industry 95 16.0 14.3 122 18.9 11.7
International 48 8.1 5.6 20 3.1 1.1
Other 132 22.2 22.8 145 22.4 n.a.
None 126 21.2 35.1 102 15.8 22.0
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proactive sociopolitical advocacy of the organisational structures
in which the majority of researchers are based, namely the
pharmaceutical and biotechnology industries. The economic
model of these organisations demands media communication as
a tool for leveraging funding and/or influencing the stock market
and shareholders. Such proactivity leads to hype and a lack of
relativism in the communication by the media of cancer research
stories, a constant theme in health literacy and public policy
(Hayes et al, 2007). Should policymakers be concerned? In
sociological terms they should be, because hype invariably leads
to unmet public expectations; the knock-on effect is a backlash
against such activities (or rather the funding of them) and a
decline in trust (Caulfield, 2004). The latter, considering the
current issues of trust around commercially driven research
anyway, is particularly damaging to the public credibility of
science (DeAngelis, 2000). Despite the fact that the story types
probably reflect the relative research activity levels in these
domains, there is a clear need to promote more balance with non-
drug cancer research stories.
The papers cited by the BBC, numbering about 1380, are
overwhelmingly from the United Kingdom (which are overcited by
the BBC by a factor of about 6) and from the United States, which
together comprise about 84% of the total. Although they tend to be
rather more clinical than the average for cancer research papers
overall, basic research is by no means neglected. They are taken
from a very wide range of journals (over 250), but three UK
journals, namely The Lancet, British Journal of Cancer, and British
Medical Journal, dominate. On average, the cited journals have
high impact factors – the mean is more than twice that for cancer
research papers overall. What these findings do suggest is that
media reporting of cancer research by the BBC is, relative to global
cancer research activity and outputs (publications), narrow. One
argument against this might suggest that important research is (a)
only published in the lingua franca of science, that is English; (b) is
thus dominated by native English speaking countries, that is the
United Kingdom and the United States; and (c) will inevitably be
published in the higher impact journals. The problem is that a high
impact journal will consequently produce research that has a high
impact on the public, but the few qualitative studies in science
have actually found a very poor correlation between the initial
impact of a paper (as defined by the journal) and its eventual
impact. The other major issue is the perceptual bias that an undue
focus on a very selective group of journals and countries has on the
public’s view of cancer research. Such situations lend too easily to
the creation of a hegemony where biases perpetuate themselves
and create a public frame of reference around cancer research that
has a false logic and consciousness (Sallach, 1974).
Finally, we have attempted to address what impact, if any, the
reporting of cancer stories by the BBC has had on the research
community. Our data suggest a possible influence, but this study
cannot rule out the possibility that the BBC news team consistently
pick higher impact papers (although this is unlikely from other
studies). How such stories impact the general public’s perception
of cancer research in all its permutations is a logical question that
can be built upon the data presented. Similarly, the variability in
which cancer research is presented through the media in different
European Member States and more widely would say much about
the different cultural perceptions towards this particular bio-
medical research domain. Cancer research does not have a well-
developed ‘third culture’ (direct researcher-to-public connection),
and hence is increasingly reliant on the diverse media for
informing and engaging the public. If the aim is to achieve a
‘public understanding of cancer’, then we need to ask how this
current interface works and whether it is achieving the aspirations
of both the public and the research community.
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